4basebio (LON:4BB) Stock Price Up 2% - Here's Why

Key Points

• 4basebio PLC's stock price rose by 2% to GBX 989 ($13.13) with a significant decline in trading volume, dropping to approximately 448 shares.
• The company reported a quarterly earnings loss of GBX (0.94) (($0.01)) per share and is projected to post an annual loss of -3.43 earnings per share for the fiscal year.
• With a market capitalization of £126.69 million, 4basebio specializes in developing therapeutic synthetic DNA for gene therapies and gene-based vaccines.

4basebio PLC (LON:4BB - Get Free Report)'s share price rose 2% on Friday . The stock traded as high as GBX 990 ($13.14) and last traded at GBX 989 ($13.13). Approximately 448 shares were traded during mid-day trading, a decline of 58% from the average daily volume of 1,069 shares. The stock had previously closed at GBX 970 ($12.87).

4basebio Stock Up 2.0%

The firm has a 50-day moving average of GBX 1,014.91 and a two-hundred day moving average of GBX 1,098.78. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The company has a market capitalization of £126.69 million, a PE ratio of -1,267.95 and a beta of 1.09.

4basebio (LON:4BB - Get Free Report) last issued its quarterly earnings results on Tuesday, May 27th. The company reported GBX (0.94) (($0.01)) earnings per share for the quarter. Equities research analysts predict that 4basebio PLC will post -3.43 earnings per share for the current fiscal year.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.